UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The cost of fall related presentations to the ED: A prospective, in-person, patient-tracking analysis of health resource utilization

Osteoporosis international, 2012-05, Vol.23 (5), p.1513-1519

2012

Volltextzugriff (PDF)

P788 The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: Results from the ELEVATE UC clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1468-i1470

2024

Volltextzugriff (PDF)

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1330-i1332

2024

Volltextzugriff (PDF)

A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis

Social science & medicine (1982), 2005-04, Vol.60 (7), p.1571-1582

2005

Volltextzugriff (PDF)

Meta-analysis of the impact of 9 medication classes on falls in elderly persons

Archives of internal medicine (1960), 2009-11, Vol.169 (21), p.1952

2009

Volltextzugriff (PDF)

SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.785-785

2015

Volltextzugriff (PDF)

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Value in health, 2017-05, Vol.20 (5), p.A180

2017

Volltextzugriff (PDF)

RI3 COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6–24 MONTH OLD CHILDREN

Value in health, 2004-05, Vol.7 (3), p.222-222

2004

Volltextzugriff (PDF)

PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

Value in health, 2004-05, Vol.7 (3), p.323-323

2004

Volltextzugriff (PDF)

PIN45: THE COST EFFECTIVENESS OF PI BASED THERAPY WITH NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH HIV/AIDS

Value in health, 2003-05, Vol.6 (3), p.268-268

2003

Volltextzugriff (PDF)

Adiposity changes after a 1-year aerobic exercise intervention among postmenopausal women: a randomized controlled trial

International Journal of Obesity, 2011-03, Vol.35 (3), p.427-435

2011

Volltextzugriff (PDF)

The association between threatened preterm labour and perinatal outcomes at term: a population‐based cohort study

BJOG : an international journal of obstetrics and gynaecology, 2021-06, Vol.128 (7), p.1145-1150

2021

Volltextzugriff (PDF)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis

Inflammatory bowel diseases, 2022-09, Vol.28 (9), p.1338-1347

2022

Volltextzugriff (PDF)

S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S675-S675

2023

Volltextzugriff (PDF)

Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians

Inflammatory bowel diseases, 2021-06, Vol.27 (7), p.1096-1106

2021

Volltextzugriff (PDF)

S1072 Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S816-S817

2023

Volltextzugriff (PDF)

S843 Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S623-S623

2023

Volltextzugriff (PDF)

The association between caesarean section and childhood obesity revisited: a cohort study

Archives of disease in childhood, 2013-07, Vol.98 (7), p.526-532

2013

Volltextzugriff (PDF)

S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S330-S331

2023

Volltextzugriff (PDF)

Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib

Journal of Crohn's and colitis, 2024-08, Vol.18 (8), p.1283-1291

2024

Volltextzugriff (PDF)

Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

Patient preference and adherence, 2020-01, Vol.14, p.119-131

2020

Volltextzugriff (PDF)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Inflammatory bowel diseases, 2021-04, Vol.27 (4), p.585-589

2021

Volltextzugriff (PDF)

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

Journal of Crohn's and colitis, 2024-06

2024

Volltextzugriff (PDF)

Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View

Inflammatory bowel diseases, 2021-11, Vol.27 (11), p.1747-1755

2021

Volltextzugriff (PDF)

POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.358-359

2022

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(29)
Humans
(17)
Female
(12)
Middle Aged
(10)
Aged
(9)
Biological And Medical Sciences
(9)
Adult
(8)
Medical Sciences
(8)
Risk Factors
(8)
Inflammatory Bowel Disease
(7)
Gastroenterology & Hepatology
(6)
Male
(6)
Public, Environmental & Occupational Health
(6)
Quality Of Life
(6)
Oncology
(5)
Surveys And Questionnaires
(5)
Case-Control Studies
(4)
Epidemiology
(4)
Materials Science
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The cost of fall related presentations to the ED: A prospective, in-person, patient-tracking analysis of health resource utilization

P788 The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: Results from the ELEVATE UC clinical programme

P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme

A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis

Meta-analysis of the impact of 9 medication classes on falls in elderly persons

SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis

COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

RI3 COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6–24 MONTH OLD CHILDREN

PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

PIN45: THE COST EFFECTIVENESS OF PI BASED THERAPY WITH NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH HIV/AIDS

Adiposity changes after a 1-year aerobic exercise intervention among postmenopausal women: a randomized controlled trial

The association between threatened preterm labour and perinatal outcomes at term: a population‐based cohort study

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis

S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program

Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians

S1072 Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program

S843 Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis

The association between caesarean section and childhood obesity revisited: a cohort study

S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib

Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials

Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View

POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS

Suchergebnisse filtern